Shows
MAP - Market Access PodcastHow will AI shape the future of Market Access and Systematic Reviews, Jeffrey Johnson and Kevin Kallmes? (Repost)This is a repost of a popular episode of MAP - Market Access Podcast, from July 15th 2024.Unlock the Future of Market Access with AI and Systematic Literature Reviews! Join Dr. Stefan Walzer in the latest episode of the Market Access Podcast as he delves into the transformative power of AI in systematic literature searches. Featuring Jeffrey Johnson and Kevin Kallmes from Nested Knowledge, this episode explores how their innovative platform revolutionizes literature reviews, making them faster, more efficient, and more enjoyable.This episode is for anyone who wants to learn more about the integration...2025-06-0134 min
MAP - Market Access PodcastHow Can Market Access Professionals Plan for Long-Term Success, Adrian Kielhorn?What does it take to succeed in Market Access? In this brand new episode of MAP, the Market Access podcast, Dr. Stefan Walzer sits down with industry veteran Adrian Kielhorn, co-author of The Market Access Guide. Together, they unpack the evolving role of market access professionals, the power of strategic thinking, mastering negotiations, and why patient centricity is key to success.Learn how to develop a strong value story, navigate pricing and reimbursement, and stay ahead in the dynamic pharmaceutical and healthcare landscape. Whether you’re a seasoned professional or just starting out, this episode is packed wi...2025-05-1538 min
MAP - Market Access PodcastWhat Are the Biggest Challenges & Opportunities of JCA, Dr. Nick Leach?In this brand new episode of MAP, the Market Access Podcast, our host Dr. Stefan Walzer is joined by Dr. Nick Leach, Market Access expert and managing director at Red Thread, to break down the Joint Clinical Assessment (JCA) process, its impact on pharma, biotech, and medical device companies, and how early advice can shape market access and reimbursement strategies in Europe.Tune in to learn about JCA’s mandatory requirements, challenges, opportunities, and future developments as companies prepare for the evolving EU market access framework. JCA is changing the market access landscape in Europe - don’t mi...2025-05-0135 min
MAP - Market Access PodcastAre We Overlooking the Real Benefits of Medical Innovation, Dr. Ahmed Seddik?Join the latest episode of the Market Access Podcast, where our host Dr. Stefan Walzer and expert Dr. Ahmed Seddik dissect the complexities of the societal impact of medical innovation. Dr. Ahmed Seddik shares important insights from his journey starting as a dentist in Egypt to his PhD research in health economics and social impact, focusing on how the access to innovation transforms communities and economies.Explore how medical innovation shapes healthcare systems and economies, and take part in the discussion of how health economics, cost-effectiveness, and societal impact influence reimbursement decisions. Listen now to learn more a...2025-04-1533 min
MAP - Market Access PodcastWhat Are the Biggest Challenges in Implementing AI in Pharma, Jan Kroschinski?How can AI revolutionize Market Access, and what does it take to drive successful change in pharma? Tune into the latest episode of MAP, the Market Access Podcast, where our host Dr. Stefan Walzer and Jan Kroschinski, an expert in digital transformation, will delve into change management and AI adoption in pharma.Follow along as they explore how AI can streamline processes like dossier writing and HTA submissions, while tackling resistance to change. Discover strategies for effective AI adoption, leadership engagement, and risk vs. opportunity - how to shift from fear-based thinking to opportunity-driven AI adoption. Get...2025-04-0143 min
MAP - Market Access PodcastHow Can Startups Leverage Market Access to Attract Investors, Johan Olsson?In the latest episode of MAP, the Market Access Podcast, our host Dr. Stefan Walzer sits down with Johan Olsson, a seasoned life sciences investor, to uncover the critical role of market access and reimbursement in early-stage healthcare investments.They explore how early market access planning impacts healthcare startups, investment decisions, and commercialization success. Discover why pricing, reimbursement, and payer strategies are key to securing funding, mitigating risk, and maximizing valuation. An understanding of the market access landscape can make or break a healthcare startup’s valuation, funding potential, and commercial viability. Tune in now to learn ho...2025-03-1533 min
MAP - Market Access PodcastHow Are Data Privacy Laws Delaying Patient Access to New Treatments, Douglas Drake and Adam Skali?In this episode of MAP, Dr. Stefan Walzer, together with experts Douglas Drake and Adam Skali, unpacks the complexities of how GDPR regulations affect real-world evidence, cross-border studies, and market access in Europe. The discussion highlights data privacy challenges, delays in commercialization, and the future of healthcare data regulation. Learn more about how data privacy laws create barriers for cross-border studies, delaying access to life-saving treatments, and how companies can navigate these hurdles and optimize market entry strategies. Can Europe find a balance between data privacy and innovation? Tune in to explore the challenges, solutions, and what’s...2025-03-0134 min
MAP - Market Access PodcastHow Can Innovation Planning Transform Market Access Success, Dr. Kasia Hein-Peters?Tune in to the latest episode of MAP, the Market Access Podcast, where Dr. Stefan Walzer sits down with Amazon bestselling author Dr. Kasia Hein-Peters to explore the power of structured innovation planning. Get a deeper understanding of how healthcare companies better can balance short-term commercialization with long-term innovation, as well as what roles of AI, digital twins and scenario-based planning play in shaping market access. Hear the expert insights on commercialization, reimbursement, and future-proofing market access strategies. From Horizon 1 (current business) to Horizon 3 (future disruptions), this episode unpacks the key strategies to ensure market a...2025-02-1533 min
MAP - Market Access PodcastHow does early Market Access bridge the gap between innovation and commercial success, Catherine Bacon?Discover the newest episode of MAP, the Market Access Podcast, your go-to podcast for all things Market Access. In todays episode our host Dr. Stefan Walzer dives deep into early market access in commercialization planning, bridging the gap between innovation and market success. Joined by Catherine Bacon, founder of Fingerpost Consulting, the conversation unpacks the critical steps early-stage healthcare companies must take to ensure patient access, maximize funding, and achieve commercial success.Explore the importance of early market access in commercialization planning. Learn how to align clinical trials, evidence generation, and payer requirements to ensure patient access...2025-02-0131 min
MAP - Market Access PodcastA Flourishing Career in Pharmaceutical Market Access: Which Skills Are Essential, Dipti Tankala? (Repost)This is a repost of a popular episode of MAP - Market Access Podcast, from March 15th 2024.Explore the inspiring journey of Dipti Tankala in this podcast episode as she delves into market access within the pharmaceutical industry. From facing challenges in community pharmacy to leading in oncology market access, Dipti shares valuable insights on making impactful career transitions. Market Access veteran Dr. Stefan Walzer and Dipti Tankala also talk about the significance of networking, mentorship, and the essential skills for success. This episode is a must-listen for professionals looking to navigate the complex world of market a...2025-01-1532 min
MAP - Market Access PodcastWhat happens, when negotiations fail, Prof. Dr. Jürgen Wasem? (Repost)This is a repost of a popular episode of MAP - Market Access Podcast, from December 15th 2021.Who could be better to tell us the real insights, how the arbitration board works than Prof. Dr. Juergen Wasem, the former head of the AMNOG arbitration board and the current head of the DiGA arbitration board. In this wide ranging conversation Dr. Stefan Walzer confronted Prof. Wasem with in-depth issues to take the arbitration board as well into strategic considerations.Take the chance to stay connected and subscribe with your favorite podcasting platform or directly liste...2024-12-1538 min
MAP - Market Access PodcastHow can people get equal access to pharmaceuticals, Dr. Nina Lathia? (Repost)This is a repost of a popular episode of MAP - Market Access Podcast, from April 15th 2023.All patients within all populations should have access to high quality medications that improve their health outcomes regardless of race, ethnicity, socio-economic status or any other individual factors, wrote Dr. Utibe R. Essien in an Jama article 2021. But how does reality look like? Equality in access starts with the generalizability of RCT data and the inclusion and exclusion criteria for these studies. But it does not stop there. How do regulators, payers and physicians work against inequality? The market access veter...2024-12-0130 min
MAP - Market Access PodcastHow might digitization change health care in Germany by 2035, Julian Molitor? (Repost)This is a repost of a popular episode of MAP - Market Access Podcast, from October 1st 2022.Digital health could improve the efficiency, care and way patients are treated in all health care systems in the next years. Germany has started by implementing digital health applications (“DIGAs”) and is currently on its way to improve the digital infrastructure in hospitals. Anyway, some core questions remain such as reimbursement for high risk medical devices, e.g. artificial intelligence (AI), interoperability.Dr. Stefan Walzer and Julian Molitor are discussing the current state as well as future opportunities with...2024-11-1531 min
MAP - Market Access PodcastHow to optimize commercialisation of innovative life science products, Dr. Kasia Hein-Peters? (Repost)This is a repost of a popular episode of MAP, Market Access Podcast, from 15th of July 2023.Even though there are great accelerators and a lot of innovative product ideas, only very few products actually make it to the market and are commercially successful. What is the reason behind that and even more important how could this situation be improved?In this podcast episode, Dr. Stefan Walzer and Dr. Kasia Hein-Peters are discussing the necessity for an overarching business and company strategy approach. In health care this is sometimes referred to a lifecycle approach, the...2024-11-0131 min
MAP - Market Access PodcastWhat does environmental sustainability mean for Market Access, Gerdi Strydom?Join us on the latest episode of MAP - the Market Access Podcast - where our host Dr. Stefan Walzer, together with special guest Gerdi Strydom, Managing Director at Valid Insight, explore the integration of ESG (Environmental, Social, and Governance) into Health Technology Assessments (HTAs).In this episode, they unpack how healthcare's carbon footprint and environmental impact are influencing policy, payor decisions, and industry strategies. Discover how leaders are addressing these challenges, the steps being taken in regions like the Nordics and the UK, and what the future holds for low-carbon pharmaceuticals.This episode is...2024-10-1534 min
MAP - Market Access PodcastWhat are the main obstacles in oncology market access, Ed Schoonveld? (Repost)This is a repost of a popular MAP, Market Access Podcast, from 1st of January 2023. Companies launching oncology drugs sometimes struggle with existing reimbursement pathways and negotiations with payers, mainly in Europe, but also in other parts of the world. Evidence generation is the start of every drug development, but especially in oncology the design is important – not only that payers want to get a proof of a longer survival, but they also have further needs in their internal assessment. Enjoy the insights shared by the oncology market access veterans Dr. Stefan Walzer and Ed Schoonveld. Stay...2024-10-0138 min
MAP - Market Access PodcastIs there a place for Real World Evidence in HTA, Dr. Karen Facey? (Repost)This is a repost of a popular MAP, Market Access Podcast, from January 2023. A strong evidence package is important as a solid base for health technology assessments and the following price negotiations with health care payers. It is widely agreed, that randomized controlled trials are the gold standard in HTA, but there are also strong advocates of real-world evidence as a complementary way to measure the effectiveness of treatments. One of these advocates is Dr. Karen Facey and so Dr. Stefan Walzer brought her on the podcast and asked all the tough questions about real wo...2024-09-1533 min
MAP - Market Access PodcastHow should market access and medical affairs work together, Dr. Mike Rosenblatt? (Repost)In this repost of MAP, the Market Access Podcast, from 15th of September 2023, you’ll hear from Dr Stefan Walzer and Dr Mike Rosenblatt as they’re discussing the age we are currently in of massive medical innovation, including a lot of new modalities especially in the area of ATMPs, and this insightful conversation highlights some core questions:- What are the differences between Clinical Development and Medical Affairs?- When should a company start telling their medical story about a new product?- What are the differences between drugs and vaccinations from a med...2024-09-0130 min
MAP - Market Access PodcastSummer Special - Webinar: How AI can revolutionize dossier writing, with special guest Aleksey ZavgorodniyTune in to the latest episode of MAP, the Market Access Podcast, hosted by Dr Stefan Walzer. In this summer special you will hear some profound insights from the recent MArS Webinar about the new platform DO-Bo - the first and only AI bot for creating reimbursement dossiers globally. Alongside Dr. Stefan Walzer you will also hear from Aleksey Zavgorodniy from Ukraine as they dive deep into how large language models are revolutionizing healthcare dossier writing.The journey to create DO-Bo highlighted unique challenges and innovative solutions. Integrating expert knowledge with AI, maintaining data security, and optimizing da...2024-08-1534 min
MAP - Market Access PodcastWhat are the latest trends in Turkish Healthcare Market Access, Oznur Seyhun?Join us on the latest episode of MAP - the Market Access Podcast - hosted by Dr. Stefan Walzer, as we delve into the dynamic world of market access in Turkey. This episode features Oznur Seyhun, from Market Access Today, who brings expertise from over 20 years of experience in pharmaceutical chemistry, economics, and global management.Explore the latest trends in healthcare market access in Turkey, and discover how they are adapting to economic challenges like inflation and currency fluctuations. Learn about the introduction of Multi-Criteria Decision Analysis (MCDA) in reimbursement submissions, the rise of digital health solutions, an...2024-08-0134 min
MAP - Market Access PodcastHow will AI shape the future of Market Access and Systematic Reviews, Jeffrey Johnson and Kevin Kallmes?Unlock the Future of Market Access with AI and Systematic Literature Reviews! Join Dr. Stefan Walzer in the latest episode of the Market Access Podcast as he delves into the transformative power of AI in systematic literature searches. Featuring Jeffrey Johnson and Kevin Kallmes from Nested Knowledge, this episode explores how their innovative platform revolutionizes literature reviews, making them faster, more efficient, and more enjoyable.This episode is for anyone who wants to learn more about the integration of AI in market access, reimbursement planning, and dossier creation. Tune in to find out how AI is not...2024-07-1534 min
MAP - Market Access PodcastHow can Virtual Reality become a game-changer in Healthcare Training, Rodrigo Silva?Tune in to the new episode of the Market Access Podcast (MAP), where Dr. Stefan Walzer, a pioneer in Market Access 4.0, explores groundbreaking solutions and innovative technologies shaping the future of healthcare reimbursement. Discover how AI-based platforms like Q-Bo and Wafle are revolutionizing health care trainings with all stakeholders.Special guest Rodrigo Silva shares his insights on the transformative power of virtual reality in healthcare, from enhancing nurse training to potential applications in the pharmaceutical industry. Discover how these technologies are revolutionizing market access and how digital health platforms can address critical healthcare challenges like nursing shortages. 2024-07-0135 min
MAP - Market Access PodcastHow Can AI Unlock the Potential of Market Access, Sandip Shah?In the latest episode of MAP - the Market Access Podcast, Dr. Stefan Walzer discusses the transformative power of AI with industry veteran Sandip Shah. With over three decades in healthcare, Sandip shares his journey from sales rep to running Market Access Solutions, emphasizing on how AI is reshaping the landscape. Discover how AI is revolutionizing market research, streamlining dossier preparation, and reshaping pricing strategies. This episode is for anyone who wants to dive deep into how the potential of AI in enhancing market research through emotion recognition and data analysis can significantly impact payer research and tra...2024-06-1538 min
MAP - Market Access PodcastHow to Decode Market Access in Canada: Are There Essential Tips for Success, Tara Cowling and Jody Filkowski?In the newest episode of MAP - the Market Access podcast, experts Tara Cowling and Jody Filkowski unpacks the complexities and nuances of Canada's market access for pharmaceuticals and medical devices. From regulatory hurdles to intricate reimbursement pathways, they shed light on what it takes to successfully navigate this diverse and challenging landscape.Whether you're dealing with drugs or medical devices, understanding the distinct processes in Canada, including the differences between provinces and the role of private versus public payers, is crucial. This episode offers a deep dive into the practical strategies and real-world challenges faced by...2024-05-1544 min
MAP - Market Access PodcastHow has virtual become reality in market access, Glib Kutepov?What role will AI & VR transformations play in the future? Tune in to this fascinating episode of the Market Access Podcast to hear as our special guest, Glib Kutepov, CEO and founder of Modulate, shares his expertise. Glib uncovers the potential of generative AI and neural networks in revolutionizing market access strategies and highlights the challenges and solutions around data privacy as well as the integration of private layers to protect sensitive information. He also touches on the role of VR in empathizing with patients' experiences, adding a deeply human element to the data-driven world of market a...2024-05-0131 min
MAP - Market Access PodcastWhat Makes Italy's Healthcare System So Complex, Giacomo Matteo Bruno?Tune into a brand new episode of the Market Access Podcast to listen to an intriguing conversation about the Italian healthcare system with Giacomo Matteo Bruno and Dr Stefan Walzer. Together they explore the balance between innovation, sustainability, and patient access in the heart of Europe. Discover the evolution, challenges, and future of healthcare in Italy, from the foundational principles laid down in 1978 to the dynamic, ever-evolving landscape of today.Giacomo shares his insights on how to navigate the crucial role of health economics in drug pathways as well as giving a birds-eye perspective over the healthcare...2024-04-1631 min
MAP - Market Access PodcastIs Healthcare Just a Business in the US, Aymeric Chaupin?In this captivating episode of MAP, the Market Access Podcast, we welcome Aymeric Chaupin, a seasoned expert in pricing and market access. Aymeric's unique perspective, shaped by his deep understanding of both the American and European healthcare systems, sheds light on the complexities of healthcare reimbursement pathways in the US and their impact on the delivery of health services.Join us as Aymeric unveils the challenges and opportunities within the US healthcare market. He emphasizes the importance of coding and understanding reimbursement pathways for effective market access and explores the broader implications for patient care and the...2024-04-0133 min
MAP - Market Access PodcastA Flourishing Career in Pharmaceutical Market Access: Which Skills Are Essential, Dipti Tankala?Explore the inspiring journey of Dipti Tankala in this podcast episode as she delves into market access within the pharmaceutical industry. From facing challenges in community pharmacy to leading in oncology market access, Dipti shares valuable insights on making impactful career transitions. Market Access veteran Dr. Stefan Walzer and Dipti Tankala also talk about the significance of networking, mentorship, and the essential skills for success. This episode is a must-listen for professionals looking to navigate the complex world of market access and leverage opportunities in the pharmaceutical field. Tune in to unlock your career potential with expert advice from a s...2024-03-1532 min
MAP - Market Access PodcastMastering US Market Access: What are proven Strategies for Success, Paul-Lukas Hoffschmidt?In this essential episode of the Market Access Podcast, we're diving deep into the critical aspects of commercializing healthcare innovations in the US market. Whether you're in medtech, pharma, biotech, or health tech, understanding the US healthcare landscape is key to your product's success. Join us as Dr. Stefan Walzer and Paul-Lukas Hoffschmidt, CEO of Alpha Sophia (www.alphasophia.com), share their wealth of knowledge on effective strategies for navigating this complex terrain.Key Topics Covered:Understanding US Market Access: An overview of the unique challenges and opportunities in the US healthcare system for new entrants.R...2024-03-0133 min
MAP - Market Access PodcastBeyond the CE Mark: How can we achieve Medtech Reimbursement in France, Dr. Benoit Salaun?Join us for a fascinating dive into the complexities of French market access with our latest episode of the Map Podcast. Dr. Stefan Walzer, health economist and founder of Mars Market Access & Pricing Strategy, engages with Dr. Benoit Salaun, a seasoned expert in French healthcare reimbursement.They unravel:The nuances of the French healthcare systemThe essentials of medical device reimbursementThe importance of demonstrating efficacy, safety, and affordabilityThe role of clinical evidence and the adaptability of international data to French contextsThe strategic considerations for medtech companies entering the French marketWhether you’re a healthcare pr...2024-02-1534 min
Next Gen Market AccessBerufsbegleitende Promotion – Fluch oder Segen, Dr. Thomas Staab?In unserer neuesten Podcast-Folge begrüßen wir Dr. Thomas Staab – er ist nicht nur Experte in seinem Feld, sondern auch Autor eines inspirierenden Ratgebers zur berufsbegleitenden Promotion. Dieses Gespräch bietet einen seltenen Einblick in die vielschichtigen Gründe und Motivationen, die hinter der Entscheidung stehen, neben dem Beruf zu promovieren. Es geht um mehr als akademische Leistungen; es geht um persönliches Wachstum, Stressmanagement und langfristige Zielsetzung.Thomas teilt seine Erfahrungen und erörtert, wie sein Buch als Navigator durch die Entscheidungsfindung dient – eine unverzichtbare Ressource für jeden, der eine Promotion in Betracht zieht. Er beleuchtet...2024-02-0536 min
MAP - Market Access PodcastRemo Christen – Early paid access in Switzerland – Switzerland, wonderland? (Repost)In this Podcast episode, Dr. Stefan Walzer is discussing the specifics of the Swiss market access & reimbursement including the famous article 71, which allows an early paid access.Who else could better speak about the Swiss system with him than Remo Christen? Remo is working since > 20 years in the Swiss market access environment in a leading role at Roche’s Swiss affiliate.In this episode, listeners will learn the specifics of the Swiss culture, the reimbursement process also in comparison to the German AMNOG and why Switzerland is attractive for drug launches.Take the ch...2024-02-0134 min
MAP - Market Access PodcastHow can we overcome the complexity of market access for medical devices in Spain, Sergio Gil?Are you intrigued by the pulsing heart of Spain’s healthcare sector, or are you considering navigating the vibrant market of medical devices in Spain? Dive into our latest Market Access podcast episode where we unravel the complexities and dynamism of Spain’s medical landscape. 🇪🇸Join us as Sergio Gil, a seasoned veteran with over three decades in the medical device industry, shares his invaluable insights. From understanding Spain's unique regional healthcare powers to decoding the reimbursement conundrums, Sergio illuminates the path to successful market entry and what makes Spain not just culturally, but commercially captivating.Here’s a...2024-01-1533 min
MAP - Market Access PodcastWhat is the secret of the cost-efficient healthcare system in Israel, Mirel Stelian? (Repost)We are looking at Israel a lot recently, but did you know how innovative this rather small country is in terms of healthcare?Israel spends only 7.6% of the GDP on healthcare – significantly less than most other Western OECD countries. At the same time, Israel has a higher life expectancy and lower infant mortality. So, better results for less money?! How does Israel do this?Dr. Stefan Walzer and Mirel Stelian are discussing in depth, how the application and reimbursement process works and what options are available for companies who want to enter the Israeli market. If you w...2023-12-1533 min
MAP - Market Access PodcastThe Startup Guide to Navigating Healthcare Reimbursement, Featuring Ron de GraaffWe are thrilled to announce our latest podcast episode, featuring a riveting conversation between our CEO Dr. Stefan Walzer and the esteemed healthcare reimbursement expert, Ron de Graaff. Ron, with his deep-rooted experience starting from 1978, shares his invaluable insights on the evolution of healthcare reimbursement, a journey from simpler times to today's intricate landscape involving multiple stakeholders like health insurance companies.🔍 Key Highlights:- Ron's path from founding his company in 1985, which has since assisted over 900 entities, including governments, in understanding medical technology markets.- Challenges faced by startups in healthcare, ofte...2023-12-0133 min
MAP - Market Access PodcastNavigating the Healthcare Startup Galaxy - key insights with Dr. Thomas Kerscher and Mark Anken.🎧 Excited to share our CEO, Dr. Stefan Walzer's newest Market Access podcast episode that's nothing short of a masterclass for healthcare startups venturing into the European market!In this engaging episode, Dr. Walzer sits down with Dr. Thomas Kerscher and Mark Anken, both titans in the healthcare and pharmaceutical sectors with over two decades of experience. Currently at the helm of advantage, they're shaping the future of startups in this complex field. 🌍Key Highlights:1️⃣ Tailored Strategies: The critical need for startups to tailor their strategies based on product type and the unique healthcare landscapes...2023-11-1534 min
MAP - Market Access PodcastHow to navigate complexities, Aurelie Moser: Market Access in Digital Health vs. Drugs?🎙️ Exciting Podcast Episode Is Here! 🎙️In this episode of our podcast series, I'm excited to share that Stefan Walzer, a seasoned reimbursement expert, hosts the incredibly talented Amelie Moser, a business consultant with two decades of unparalleled expertise in market access!🎯 What's Happening?Immerse yourself in the fascinating world of digital health and see how it sharply contrasts with traditional drug landscapes.Grasp the challenges of moving global product strategies into local implementations, all through the lens of Aurelies experience.Navigate the crucial role of ecosystem mapping, and learn why it's impo...2023-11-0132 min
MAP - Market Access PodcastAMNOG 2.0 - significant changes for the industry since January 2023, correct - Dr. Flume?Join us in the latest episode where pharmacist and head of a regional physicians association, Matthias Flume, engages in a thought-provoking discussion with host Stefan Walzer, exploring the intricate tapestry of reforms enveloped within the AMNOG (Arzneimittelmarktneuordnungsgesetz) 2.0, especially scrutinizing those unveiled in 2023!🚀 Dive Deep into the Core of Pharmaceutical Reforms!Matthias unearths various pivotal changes, including the mandated discounts for products with no additional benefit rating and the perceptible adjustments in the orphan drug area, dissecting the threshold reduction for annual sales in the full regular benefit assessment. 🚀🌎 Explore the Global Im...2023-10-1531 min
MAP - Market Access PodcastHow to navigate complexities, Aurelie Moser: Market Access in Digital Health vs. Drugs?🎙️ Exciting Podcast Episode Is Here! 🎙️In this episode of our podcast series, I'm excited to share that Dr. Stefan Walzer, a seasoned reimbursement expert, hosts the incredibly talented Aurelie Moser, a business consultant with two decades of unparalleled expertise in market access!🎯 What's Happening?Immerse yourself in the fascinating world of digital health and see how it sharply contrasts with traditional drug landscapes.Grasp the challenges of moving global product strategies into local implementations, all through the lens of Aurelies experience.Navigate the crucial role of ecosystem mapping, and learn why it...2023-10-0132 min
MAP - Market Access PodcastInside the Swiss decision-makers - how does the system for drugs really work, Dr. Heiner Sandmeier?Listen to this podcast on your favourite podcast player: https://lnkd.in/eGemZRTi Switzerland is seen as a small but still attractive market for pharmaceuticals, even though that the Swiss decision-makers are considered as tough and sometimes even difficult. A core issue might especially be, that the assessment and negotiations primarily happen intransparently „behind the doors“. Dr. Heiner Sandmeier has been part of the drug evaluation committee advising the Swiss decision makers for over a century and opens his insights and secrets to all listeners. Some of the topics Dr. Sandmeier and reim...2023-10-0136 min
MAP - Market Access PodcastHow should market access and medical affairs work together, Dr. Mike Rosenblatt?Listen to this podcast on your favourite podcast player: https://lnkd.in/eGemZRTiWe are living in an age of massive medical innovation including a lot of new modalities especially in the area of ATMPs, but also beyond. Within this area, but obviously also beyond, there are core questions in the area of tensions such as the followings:- What are the differences between Clinical Development and Medical Affairs?- When should a company start telling their medical story about a new product?- What are the differences between drugs and va...2023-09-1530 min
MAP - Market Access Podcast📠 How will Switzerland make the leap from FAX machines to Digital Healthcare, Dr. Peter Indra?🎧 Listen to this podcast on your favourite podcast player: https://lnkd.in/eGemZRTi 🇨🇭Switzerland has one of the highest healthcare spendings per person across the world! At the same time, one could also say that Switzerland has also one of the best healthcare systems... 💥 … but health care expert Dr. Peter Intra calls it still a developing country in terms of digitalisation! In this MAP podcast episode, health care system veteran Dr. Stefan Walzer and Dr. Peter Indra are discussing the current state of digital health in Switzerland, possible improvements and the inspiring example of Estonia.What are we ta...2023-09-0129 min
MAP - Market Access PodcastHow does an optimized communication strategy look like, Dr. Arne Näveke?Listen to this podcast on your favourite podcast player: https://lnkd.in/eGemZRTiCompanies, including start-ups, are usually focused solely on the development of the product and/or the technical platform in the early days. As understandable and important these aspects are, if they don’t start to think about their public communications strategy from the very beginning, they might be in danger of failing. Already in the very early stages of the development of pharmaceuticals or med tech products, companies need to think about the following key points: Will patients need and want the new product?Will physicians prescribe it?...2023-08-1532 min
MAP - Market Access PodcastHow does the German evaluation committee work, Prof. Jürgen Wasem?Listen to this podcast on your favourite podcast player: https://lnkd.in/eGemZRTi New methods such as diagnostics need to be assessed and the included in the reimbursement catalogue in the outpatient setting in Germany. However, key question remains which requirements are needed for such an evaluation and who is responsible for it. In some instances the responsible body is a sub-committee of the German federal Committee (G-BA) the so-called evaluation committee. But how does that body come to a conclusion and what do they really assess. How does price setting work in such an en...2023-08-0134 min
MAP - Market Access PodcastHow to optimize commercialisation of innovative life science products, Dr. Kasia Hein-Peters?Even though there are great accelerators and a lot of innovative product ideas, only very few products actually make it to the market and are commercially successful. What is the reason behind that and even more important how could this situation be improved?In this podcast episode, Dr. Stefan Walzer and Dr. Kasia Hein-Peters are discussing the necessity for an overarching business and company strategy approach. In health care this is sometimes referred to a lifecycle approach, the invented approach by Dr. Kasia Hein-Peters is called DIVE. Within these approaches, all stakeholders would always need to be...2023-07-1531 min
MAP - Market Access PodcastHow do I get approved by the US FDA, Dr. Jamie Cross?In order to commercialize a health care product in the USA, the US FDA would need to approve it. But what is the standard process and how early would a company need to be involved and maybe even get advice? Additionally, the core question remains how could US FDA requirements be aligned with potential payer needs - are there any relationships?The #marketaccess veterans Dr. Stefan Walzer and Dr. Jamie Cross are discussing the principles as well as some very specific details. ✏️ Take the chance to stay connected and subscribe with your favorite podcast platform: https...2023-07-0146 minMAP - Market Access PodcastHow will the US Inflation Reduction Act change pricing of pharmaceuticals, Anita Burrell?The Inflation Reduction Act in the US will change fundamental how the US pharmaceutical industry works. The IRA will negotiate their own prices for Medicare and Medicaid, which will have the result, that they will not pay the same prices in the future anymore.With Medicare the government directly funds pharmaceuticals for 65+ years old population.With Medicaid the government fund low income and other vulnerable populations.Given, that the private insurance sector will follow the lead of government negotiated prices, all prices will decrease.Revenues in the US will d...2023-06-1535 minMAP - Market Access PodcastHow does market access work in Japan, Heather Wellam?The market access experts Dr. Stefan Walzer and Heather Wellam are discussing the market access process in Japan, one of the largest health care markets in the world!In Japan not all products need to go through the full process, so an important question is, what the criteria are and what role does cost-effectiveness play in this market? What are the differences in the process between drugs and medical devices?On top, the two experts are also discussing the opportunity to apply for price premiums in the reimbursement process. Take the chance to st...2023-06-0130 min
Next Gen Market AccessWie sorgt die Schiedsstelle im Bereich des AMNOGs konkret für eine (finale) Preisfindung?Die Schiedsstelle kann eine wichtige Institution im Bereich des AMNOGs sein, wenn sich die beiden Parteien nicht einigen können.Dabei stellen sich verschiedene Fragen: Wie wird die Höhe des zu Erstattungsbetrags festgelegt? Welche Schwierigkeiten gibt es dabei und was hat sich über die letzten Jahre verändert? Die StudentInnen der DHBW Lörrach schauen sich konkrete Fallbeispiele an und erklären daran das Vorgehen der (AMNOG) Schiedsstelle.Dieser Podcast wurde produziert von Dr. Stefan Walzer (MArS https://marketaccess-pricingstrategy.de/) und StudentInnen der DHBW Lörrach.2023-05-2232 minMAP - Market Access PodcastWould AI substitute or (only) support market access managers, Dr. Andree Bates? (Repost)Since the original publication of this podcast, AI has received enormous public attention, and we have also seen an amazing increase in performance. This makes this discussion even more relevant - with this REPOST we want to give you the opportunity to hear it, in case you missed the first publication. Dr. Stefan Walzer, market access expert, and his guest Dr. Andree Battes, expert in artificial intelligence (AI), are discussing the future of market access within the health care industry. How could AI support market access planning, submissions and negotiations, especially with the ever-increasing data? How could AI b...2023-05-1531 minNext Gen Market AccessWie funktioniert die Preisverhandlung im Rahmen des AMNOG Verfahrens?Welchen Preis eine neue Therapie haben soll, entscheidet sich im Rahmen einer festgelegten Verhandlung. Dabei spielen verschiedene Faktoren und Zielsetzung eine Rolle. Aber wer entscheidet bzw verhandelt über die Erstattungsbeträge und welche Probleme können bei der Verhandlung auftreten?StudentInnen der DHBW Lörrach stellen sich diesen Fragen und bieten konkrete Lösungsansätze für einige der aufkommenden Probleme.Dieser Podcast wurde produziert von Dr. Stefan Walzer (MArS https://marketaccess-pricingstrategy.de/) und StudentInnen der DHBW Lörrach.2023-05-0842 minMAP - Market Access PodcastIs there a place for Real World Evidence in HTA, Dr. Karen Facey?A strong evidence package is important as a solid base for health technology assessments and the following price negotiations with health care payers. It is widely agreed, that randomized controlled trials are the gold standard in HTA, but there are also strong advocates of real-world evidence as a complementary way to measure the effectiveness of treatments. One of these advocates is Dr. Karen Facey and so Dr. Stefan Walzer brought her on the podcast and asked all the tough questions about real world evidence and the reality with payers around the world. Are there opportunities in such R...2023-05-0133 minMAP - Market Access PodcastHow can people get equal access to pharmaceuticals, Dr. Nina Lathia?All patients within all populations should have access to high quality medications that improve their health outcomes regardless of race, ethnicity, socio-economic status or any other individual factors, wrote Dr. Utibe R. Essien in an Jama article 2021. But how does reality look like? Equality in access starts with the generalizability of RCT data and the inclusion and exclusion criteria for these studies. But it does not stop there. How do regulators, payers and physicians work against inequality? The market access veteran Dr. Stefan Walzer and the Canadian health economist Dr. Nina Lathia have discussed these pharmacoequity issues from a global p...2023-04-1529 minMAP - Market Access PodcastHow to be successful in Canadian health care market access & pricing!Canadian health care reimbursement might be seen as complex and difficult. Well, not totally wrong… The reimbursement veteran Dr. Stefan Walzer discusses with the Canadian experts Louise Perrault and Nicole Tunstall the process for reimbursement and the specifics of Quebec. What are requirements and what might be important early steps to consider in order to plan for success. Additionally, the pricing is being considered, especially the various institutions and the way to get prices negotiated and agreed within the health care system in Canada. Take the chance to stay connected and subscribe with your...2023-04-0145 minMAP - Market Access PodcastHow can companies prepare for EU Joint HTA, Priyanka Kiritharan and Chloe Sheppard?EU Joint HTA will become reality for ATMPs and therapies in oncology by the end of 2024. Anyhow, methods and processes are not yet communicated and established as of March 2023. Furthermore, there are no opportunities for early consultation to plan clinical trials and/or EU joint HTA dossiers. The core question still remains for which endpoints and comparators data would need to be submitted and by when? What would happen if the EMA label changes last minute with an impact on joint HTA assessments. Furthermore, nobody yet knows how these results will be implemented by national payers. More established HTA s...2023-03-1535 minMAP - Market Access PodcastIs quality cancer care in Ukraine still possible, Yevgen Brovko?Cancer care is a challenge in all countries. Now imagine, how difficult it is to organize and manage cancer care in a war zone! In this special MAP Podcast episode the Ukrainian market access expert Yevgen Brovko explains the situation and market access of cancer care before the Russian invasion and the current state in Ukraine. After a more broad overview, he also explains the Ukrainian health care system in general and explicitly in the oncology area, how new treatments are made available and the steps to launch into the Ukrainian market.Finally, the market acc...2023-03-0121 minNext Gen Market AccessWelche Spezifika existieren bei der Bewertung von pädiatrischen Arzneimitteln im Bereich des AMNOG?Der Gemeinsame Bundesauschuss (G-BA) ist auch für die Nutzenbewertungen von pädiatrischen Arzneimitteln zuständig. Spezifika bei diesen Medikamenten existieren allerdings nicht erst bei der Nutzenbewertung, sondern bereits im Vorfeld: Was haben Ethikkommission, Studienrekrutierung und Evidenztransfers von Studien mit Erwachsenen hierbei zu tun? Und wie könnte dies gelöst werden?Die Student:Innen Danika, Isabell, Kim und Marie der DHBW Lörrach setzen sich mit diesen Fragen auseinander.Dieser Podcast wurde produziert von Dr. Stefan Walzer (MArS https://marketaccess-pricingstrategy.de/) und Student:Innen der DHBW Lörrach.2023-02-2750 minMAP - Market Access PodcastWhat are drivers for a positive approval by Health Canada, Fraidianie Sévignè?Regulatory processes might vary across the world, EMA and FDA are mostly known, but what are drivers by Health Canada? What to consider when expanding e.g. from the US into Canada with a medical device? Are there differences between US FDA and Canadian decisions for drugs? And if so, why? The reimbursement veteran Dr. Stefan Walzer and the regulatory expert for Canada, Fraidianie Sévignè, discuss and recommend steps to consider for medical device and pharmaceutical companies. Take the chance to stay connected and subscribe with your favorite podcasting platform or directly listen on our...2023-02-1532 minNext Gen Market AccessWie entscheidet der GBA über den Zusatznutzen von neuen Behandlungsoptionen im Mammakarzinom?Der GBa (Gemeinsamer Bundesausschuss) ist für die Zusatznutzenbewertung von neuen Therapien in Deutschland zuständig. Darauf basierend verhandeln anschließend der pharmazeutische Unternehmer und der Spitzenverband der gesetzlichen Krankenkassen den Erstattungsbetrag. Doch wie trifft der G-BA seine Entscheidungen über den Zusatznutzen? Was sind dafür die Entscheidungskriterien und was versteht man in diesem Zusammenhang unter einer Patientenrelevanz? Student:Innen der DHBW Lörrach setzten sich damit auseinander und gehen auf konkrete Therapien und deren Bewertung ein. Dieser Podcast wurde produziert von Dr. Stefan Walzer (MArS https://marketaccess-pricingstrategy.de/) und Student:Innen der Dualen Hochschule Baden-Wür...2023-02-1323 minMAP - Market Access PodcastEU joint HTA – decided, but how will it be executed and how should companies prepare, Dr. Elvira Müller?In Europe, there are at least as many reimbursement assessment processes in place as European countries. Some of these are transparent and clearly defined like the German AMNOG process, others are even more complex and sometimes even unclear, dependent also on the product of interest. Anyhow, the European Commission has already decided that a European joint assessment will come into place in 2025 starting with oncology and ATMP products. Anyhow, currently timelines and national processes to implement the outcomes of the European evaluation are still unclear and to be defined. Dr. Stefan Walzer and Dr. Elvira Mueller discuss the current s...2023-02-0133 minNext Gen Market AccessDiabetes Mellitus und das deutsche AMNOG Verfahren - kann das funktionieren?In dieser Folge des Next Gen Market Access Podcasts geben Studentinnen einen Überblick über die Möglichkeiten und Herausforderungen in der Erstattung von (neuen) Diabetes Therapien in Deutschland. Welche Formen von Diabetes existieren? Welche medikamentösen Therapien gibt es? Für die Erstattung muss der Hersteller durch das bekannte AMNOG Verfahren mit all seinen Unwägbarkeiten. Können die Vorgaben des G-BAs und des IQWiGs bei Diabatestherapien angewandt werden bzw. wo sind ggf. die Problemfelder?Dieser Podcast wurde produziert von Dr. Stefan Walzer (MArS https://marketaccess-pricingstrategy.de/) und Student:Innen der Dualen Hochschule Baden Württemberg in L2023-01-2224 minMAP - Market Access PodcastThe US pricing reform has an impact on Europe as well, correct Dr. Renato Dellamano and Jack Mycka?!It seems to be a given, that prices in the US are higher than in the rest of the world. But what might happen, if the US refuses to pay these higher amounts anymore? There are already changes either approved or heavily discussed like the pricing inflation act, the cap on out-of-pocket cost and the opportunity for Medicare negotiating prices starting in 2026. If the global price system changes, it will become even more important to get the price right from the beginning.Those and other questions are discussed by the market access and pricing experts Dr. Stefan W...2023-01-1536 minMAP - Market Access PodcastWhat are the main obstacles in oncology market access, Ed Schoonveld?Companies launching oncology drugs sometimes struggle with existing reimbursement pathways and negotiations with payers, mainly in Europe, but also in other parts of the world. Evidence generation is the start of every drug development, but especially in oncology the design is important – not only that payers want to get a proof of a longer survival, but they also have further needs in their internal assessment. Enjoy the insights shared by the oncology market access veterans Dr. Stefan Walzer and Ed Schoonveld. Take the chance to stay connected and subscribe with your favorite podcasting platform or direct...2023-01-0138 minMAP - Market Access PodcastWhy should companies get early advice from payers, Esther Nzenza and Dr. Nick Leach?In Europe there are many different options to get engaged with payers across different jurisdictions. Given the complexity, the benefit of these might be questioned by some. However, if the pathway is clear and the company knows how to approach payers and asks the right questions it provides valuable insights securing commercial success. Within the podcast the European, UK and German pathways are being discussed including how to approach payers and what to ask them. Get the right insights from a great discussion between these market access experts! Take the chance to stay connected and su...2022-12-1538 min
Let's Combinate - Drugs + Devices062 - Reimbursement in Europe, Access, Rebates, and Negotiation with Stefan WalzerI love talking to fellow podcasters and on this episode, I was joined by Dr. Stefan Walzer, the CEO of MArS Market Access & Pricing Strategy.
Stefan discusses:
Discounts, Rebates, and how Co-Payment is different in Europe
How data is presented to payers in Europe and European Reimbursement
Germany/AMNOG Process
Negotiation
Dr. Stefan Walzer is a healthcare economist, podcaster, and CEO of MArS Market Access & Pricing Strategy GmbH based in Germany. He previously worked as a payer consultant for various global pharmaceutical and medical device / diagnostic companies, successfully launching their products across the world. Dr. Walzer was also the Global P...2022-12-0737 minMAP - Market Access PodcastThe AMNOG process - how does it work from a legal perspective, Alexander Meier?New, innovative drugs are assessed within the so-called AMNOG process in Germany. Given the legal nature of this process, lawyers also play an important role. At the end of the AMNOG process there is a legal contract – and also important, lawyers are experienced in negotiations by nature? If this is true and how lawyers can support market access teams is discussed between the AMNOG expert Dr. Stefan Walzer and the experienced market access lawyer Alexander Meier.Take the chance to stay connected and subscribe with your favorite podcasting platform or directly listen on our website: https://lnkd.in/d...2022-12-0139 minNext Gen Market AccessWas sind ATMPs und wie werden diese erstattet?Mit ATMPs (Advanced Therapy Medicinal Products) sind Therapien für Krankheiten möglich, die noch vor wenigen Jahren als unheilbar galten. Aber welche Evidenzbasis haben diese und wie wird damit auf Erstattungsebene umgegangen? Was gibt es besonderes bei diesen speziellen Therapien zu beachten?Die Studenten der DHBW Lörrach Lukas Kieffer, Alessio Lecca und Samuel Florian Probst haben die Fragen rund um ATMPs genauer unter die Lupe genommen. Dieser Podcast wurde produziert von Dr. Stefan Walzer (MArS https://marketaccess-pricingstrategy.de/) und Student:Innen der DHBW Lörrach.2022-11-2531 minMAP - Market Access PodcastWhat are the hot topics in market access based on ISPOR Europe 2022, Dr. Stefan Walzer?In this special podcast episode Dr. Stefan Walzer jumps into the latest trends and researches around market access, reimbursement and pricing presented and discussed just beginning of November 2022 at ISPOR Europe. From 6th to 9th of November the leading European experts including Dr. Stefan Walzer have met and discussed in Vienna. Discussion topics ranged widely around market access and pricing including buckets being discussed within this episode: 1) ATMPs 2) EU joint HTA 3) Digital Health 4) Germany / AMNOG 5) European reimbursement Please enjoy this compressed summary and let us know...2022-11-1552 minNext Gen Market AccessWas passiert, wenn es Probleme in der Preisfindung für DIGAs gibt?Digitale Gesundheitsanwendungen (DIGAs) kommen mehr und mehr im Alltag von Ärzt:Innen und Patient:Innen an. Wie sieht jedoch eine angemessene Preisgestaltung für DIGAs aus und was passiert, wenn GKV und Hersteller der DIGAs sich nicht einig werden?Dann kommt die Schiedsstelle ins Spiel. Im heutigen Next Gen Market Access Podcast erklären die Studentinnen Pia Aschenbrenner, Jana Willhalm und Larissa Göck was es mit der Schiedsstelle auf sich hat, wer Teil davon ist und wie sie funktioniert.Dieser Podcast wurde produziert von Dr. Stefan Walzer (MArS https://marketaccess-pricingstrategy.de/) und Student:Innen der R...2022-11-0729 minMAP - Market Access PodcastAMNOG Reform - will Germany remain the most attractive market for orphan drugs?Given the current reforms and adaptions in the German system, one can wonder if the German market might remain the most attractive to launch pharmaceutical products and especially orphan drugs. Are there still ways to get innovative products into the market and get paid well? What do we need to know in order to still gain from the strengths of the German market size and economic power? This might be an even more important question in a global climate of declining prices. This podcast was recorded as part of the „Let‘s talk rare“ podcast. In this discuss...2022-11-0141 minNext Gen Market AccessHelfen digitale Gesundheitsanwendungen im Bereich der Hormone und Stoffwechsel?Die seit 2020 in Deutschland verfügbaren DIGAs bieten auch für Erkrankungen im Bereich der Hormone und Stoffwechsel neue Möglichkeiten. Angesichts der Tatsache, dass jeder 11. Erwachsene in Deutschland unter Diabetes leidet und jeder 4. Erwachsene adipös ist, gibt es hier ein großes Feld für digitale Innovationen. Die Studentinnen Moana Hösch, Julia Palavestric, Elena Tagadrjan und Alisa Billstein, haben sich die entsprechenden Anwendungen aus dem DIGA Verzeichnis genauer angesehen. Dieser Podcast wurde produziert von Dr. Stefan Walzer (MArS https://marketaccess-pricingstrategy.de/) und Student:Innen der Ravensburg-Weingarten Fachhochschule. 2022-10-2138 minMAP - Market Access PodcastWhy should Market Access Managers care about statistics, Alexander Schacht?Not everybody can be a statistician, but >The Effective Statistician2022-10-1535 minNext Gen Market AccessHelfen digitale Gesundheitsanwendungen wirklich bei Angst- und Panikstörungen?DiGAs sind seit 2020 verfügbar, viele im Bereich der seelischen Gesundheit. Aber wie sieht die Evidenzlage und Anwendung wirklich aus? Was sagt die junge Generation zu dieser Therapie „der zukunft“? Bei der ersten Folge des Next Gen Market Access Podcasts sprechen die Student:innen Aline Ezelsberger, Annalena Birkle, Jonas Jost und Noel Steinhilper über die Evidenzlage, die Preisgestaltung sowie die bereits erfolgte Anwendung von Apps zur Behandlung von Angst- und Panikstörungen. Lernt mehr über die dafür zu erfüllenden Kriterien und die beobachteten Auswirkungen auf die Markt-Adaption. Dieser Podcast wurde produziert von Dr. Stefan Walzer (MArS https...2022-10-0736 minMAP - Market Access PodcastHow might digitization change health care in Germany by 2035, Julian Molitor?Digital health could improve the efficiency, care and way patients are treated in all health care systems in the next years. Germany has started by implementing digital health applications (“DIGAs”) and is currently on its way to improve the digital infrastructure in hospitals. Anyway, some core questions remain such as reimbursement for high risk medical devices, e.g. artificial intelligence (AI), interoperability.Dr. Stefan Walzer and Julian Molitor are discussing the current state as well as future opportunities with digital tools across the health care system. If you need to know where the German adoption is with resp...2022-10-0130 minMAP - Market Access PodcastAre selective contracts with German insurances a smarter reimbursement pathway, Tim Hering?Within the opportunity of contracting in the German health care market, prices, reimbursement and integrated care paths could be agreed on. However, for some medical devices, especially in the outpatient setting, selective contracts could be the most attractive pathway to enter into reimbursement agreements. Dr. But which health insurance companies should contacted and how? What makes a contarct attractive for a health insurance?Stefan Walzer and Tim Hering, experienced in integrated care contracts, are discussing the unique possibilities with smart contracts. Don’t miss this insightful conversation!Take the chance to stay connected and su...2022-09-1528 minMAP - Market Access PodcastWould AI substitute or (only) support market access managers, Dr. Andree Bates?Dr. Stefan Walzer, market access expert, and his guest Dr. Andree Battes, expert in artificial intelligence (AI), are discussing the future of market access within the health care industry. How could AI support market access planning, submissions and negotiations, especially with the ever-increasing data? How could AI be beneficial in defining an optimal price anchor? And finally, would AI substitute the market access manager roles within the industry?Further reading is available on "How to Embed AI into the Market Access Process“: https://eularis.com/resources Take the chance to stay connected and subs...2022-09-0131 minMAP - Market Access PodcastHow successful is the DiGA fast track, Dr. Henrik Matthies ?Dr. Matthies used to be at the epicenter of the DIGA launch in 2020. He was the managing director of the Health innovation hub: digital health think tank of the federal ministry of health in Germany. The first project of agile lawmaking in Germany. What are key takeaways and learnings from 2 years DiGAs? What are pitfalls with a focus on BfArM and the German payers (GKV-SV)? How to be successful in the German DiGA environment?Take the chance to stay connected and subscribe with your favorite podcasting platform or directly listen on our website: https://lnkd.in/dZtyKw8B...2022-08-1533 minMAP - Market Access PodcastThe UK market access has always been complex, now even more than before, Graham Foxon and Paul Craddy?The UK has always been on the forefront of market access with its unique pathways within England, but especially also considering Wales, Ireland and Scotland as well. Furthermore, since the Brexit there were new innovation paths introduced. The core question remains, how one could identify the optimal path for their product (including digital health)…Dr. Stefan Walzer and his guests Dr. Paul Craddy and Dr. Graham Foxon from Remap Consulting are discussing these and many other questions around market access in the UK. Take the chance to stay connected and subscribe with your favorite podcasting platform...2022-08-0133 minMAP - Market Access PodcastSwitzerland is strong in many aspects, so also in its health care system, Dr. Peter Indra?The Swiss healthcare system is rather complex but at the same time quite effective. High expenditures into health care corresponds with high life expectancy. However, what are the core processes in Switzerland with regards to health care delivery? What is the path towards innovation pricing and new price models? And what is the status quo on (health care) digitalization? Dr. Stefan Walzer discusses with Dr. Peter Indra one of the core stakeholders in the Swiss system with a wide ranging experience in the board of the Swiss payer institution BAG, core insurance companies and federal po...2022-07-1534 minMAP - Market Access PodcastAMNOG was the end of paradise for pharmaceutical companies, correct Prof. Hammerschmidt?What have been the main changes after 10 years of AMNOG for pharmaceutical companies? What have been the biggest successes within these years? For orphan drug the benefit evaluation process was eased in order to keep incentives high. Have price expectations been up met - by both sides? After 10 years of AMNOG first conclusions and recommendations for changes can be made. Take the chance to stay connected and subscribe with your favorite podcasting platform or directly listen on our website: https://lnkd.in/dZtyKw8B MAP is the first and only bi-weekly mar...2022-07-0137 minMAP - Market Access PodcastWhat is the secret of the cost-efficient healthcare system in Israel, Mirel Stelian?Israel spends only 7.6% of the GDP on healthcare – significantly less than most other Western OECD countries. At the same time Israel has a higher life expectancy and lower infant mortality. So, better results for less money?! How does Israel do this?Dr. Stefan Walzer and Mirel Stelian are discussing in depth, how the application and reimbursement process works and what options are available for companies who want to enter the Israeli market. If you want to understand the Israeli health care market and specifically the reimbursement process in Israel, you should not miss this episode. Take the c...2022-06-1533 minMAP - Market Access PodcastDutch payers are pragmatic, especially when discussing medical devices, isn’t it, Ron de Graaff?The market access process in the Netherlands can be very special, especially for medical devices. Besides standard reimbursement processes with evidence-based medicine assessments, there are also more pragmatic pathways available. How do these work and what needs to be considered before moving into the Dutch health care market? Listen to the insightful discussion of Dr. Stefan Walzer and the Dutch market access expert Ron de Graaff.Take the chance to stay connected and subscribe with your favorite podcasting platform or directly listen on our website: https://lnkd.in/dZtyKw8B MAP is the fir...2022-06-0134 minMAP - Market Access PodcastThe Belgium reimbursement pathway for digital health applications is similarly easy as in Germany, correct Katrien de Groote?Belgium has created a similar fast-track process as in Germany even though that some differences exist. Anyway, core question with new processes is always how the rules are being interpreted and applied. So, how important are clinical studies and when are those required? What are the price levels and negotiations components of the process? Can companies with a successful track record in Germany also be successful in Belgium?Dr. Stefan Walzer and the Belgian market access expert Katrien de Groote are discussing these and other aspects around digital healthcare in Belgium. Don’t miss these ins...2022-05-1520 minMAP - Market Access PodcastIs European market access really so difficult? Tell us the truth being successful in Europe, Esther Nzenza!Europe is one continent, with one Union (plus the UK)… Health policy is still the responsibility of each individual country and hence there are still (at least) as many reimbursement pathways as countries. Planning for business success in health care is hence difficult? Not necessarily according to Dr. Stefan Walzer and Esther Nzenza. Both show up important topics and to dos in order to plan and execute successfully. As a summary, local access leaders have a critical role and (obviously) R&D, Medical Affairs, Commercial, Regularity, Supply Chain all need to have a common touchpoint within market access. D...2022-05-0127 minMAP - Market Access PodcastWhat can Europeans learn from Canada for the upcoming EU joint HTA, Gabriel Tremblay?EU joint HTA will become reality in the next few years as communicated recently by the European Commission. However, applicability and implementation questions are still open such as timing, inclusion into national regulations and HTA processes in the EU member states. In Canada a similar process, including a single joint HTA process which is then being implemented in the respective provinces, has been introduced early 2000s. Core question remains what could be learned by European health care systems especially with respect to reimbursement and market access.The dedicated debate is lead by Dr. Stefan Walzer who is...2022-04-1543 minMAP - Market Access PodcastDigital Health Care is already fully utilized in the US, isn’t it?Dr. Stefan Walzer and Kate Claessens, the experienced consultant on healthcare in the US, are discussing the public acceptance as well as the various reimbursement pathways in the USA. What is the status of digital health care in the USA? How does reimbursement work for the different paths? What changes might we expect with the Biden administration? And what are the next steps to take?In order to make it even more practical, Anna Forsythe the Managing Partner at Purple Squirrel Economics and expert in global product commercialization and strategic drug development, has joined the discussion in the second ha...2022-04-011h 01MAP - Market Access PodcastDoes the Italian reimbursement pathway allow for innovative drugs being highly priced, Dr. Stefano Capri and Dr. Entela Xoxi?The Italian reimbursement system is unique in terms of its structure, especially also for innovative drugs. However, what does the new innovation pathway means to the industry and health care availability? How easy is it really to negotiate a premium price? Listen to the discussions and explanations of Dr Stefan Walzer and his experts from Italy Prof. Dr. Stefano Capri and Dr. Entela Xoxi. Take the chance to stay connected and subscribe with your favorite podcasting platform or directly listen on our website: MArS🎙 https://marketaccess-pricingstrategy.de/en/map-podcast/Apple 🍏 https://podcasts.apple.com/de/podcast/map-market-access-podcast/i...2022-03-1528 minMAP - Market Access PodcastWhat are the specific elements about the Austrian market access pathway, Dr. Anna Bucsics?The Austrian market access pathway in the outpatient setting is unique in its pragmatic approach with their box system.The two experts on the Austrian market, Dr. Stefan Walzer and Dr. Anna Bucsics, discuss about the pathways in Asutria but also the similarities between Germany and the Austrian system. On top, the joint EU HTA approach will also be included in a scenario analysis in terms of implementation. Listen into this breakthrough discussions with a span between Austria, Germany the EU.Take the chance to stay connected and subscribe with your favorite podcasting platform or d...2022-03-0130 minMAP - Market Access PodcastThe private health insurances as the entrance into German market access – is this true, Dr. Bastian Biermann?The German health care system consists of the statutory and private health insurances, whereas the latter covers around 10% of the population. Anyhow, access and commercialization, especially of new and innovative therapies could firstly be introduced through the private system. What are the core differences to follow with such a strategy? What are the specifics of the private health insurances? And are there examples of such a market access pathway? Dr. Stefan Walzer and Dr. Sebastian Biermann, representative of the Association of the private health insurance funds are discussing these questions and beyond. ...2022-02-1535 minMAP - Market Access PodcastHow can a company derive the optimal price for their medical product, Dr. Renato Dellamano?What are drivers of pricing and ultimately negotiations? How can a global strategy best be implemented in individual countries? How do payers react to different prices? And finally the two pricing experts Dr. Stefan Walzer and Dr. Renato Dellamano discuss philosophically whether pricing is rather an art or science… Take the chance to stay connected and subscribe with your favorite podcasting platform or directly listen on our website: https://lnkd.in/dZtyKw8B MAP is the first and only bi-weekly market access podcast provided by MArS. For more information about MArS Market Access and P...2022-02-0132 minMAP - Market Access PodcastHow do innovations reach patients in German hospitals, Dr. Sebastian Casu?How important are the famous NUBs, OPS and DRG values? How can innovations reach patients beyond administrative barriers? What are the next steps in terms of digitalization of health care in Germany? Dr. Stefan Walzer and Dr. Sebastian Casu – medical doctor and medical influencer - are continuing the conversation about inpatient market access processes with a strong focus on bed-side innovation including digitalization of healthcare. This episode is linked to episode 9 with Willi Wöllner and the hospital business administration perspective (from January 1 2022). Take the chance to stay connected and subscribe with your favorite podcasting platform...2022-01-1532 minMAP - Market Access PodcastHow does hospital funding work in Germany, Willi Wöllner?How does reimbursement work in the German hospital setting and how are hospitals organized doing such negotiations? What is a NUB and how does this relate to annual hospital budget discussions with the health insurance funds? Can industry really take part in this process?Dr. Stefan Walzer and the experienced hospital adminstrator Willi Wöllner are going deep on inpatient settings from a business perspective. Part II from a medical perspective will follow in the next episode with Dr. Sebastian Casu.Take the chance to stay connected and subscribe with your favorite podcasting platform.For mor...2022-01-0136 minMAP - Market Access PodcastProf. Dr. Jürgen Wasem - What happens, when negotiations fail?Who could be better to tell us the real insights, how the arbitration board works than Prof. Dr. Juergen Wasem, the former head of the AMNOG arbitration board and the current head of the DiGA arbitration board. In this wide ranging conversation Dr. Stefan Walzer confronted Prof. Wasem with in-depth issues to take the arbitration board as well into strategic considerations.Take the chance to stay connected and subscribe with your favorite podcasting platform.For more information about MArS Market Access and Pricing Strategy visit: marketaccess-pricingstrategy.de2021-12-1538 minMAP - Market Access PodcastDr. Michael Zuercher - Commercial attractiveness of the Swiss health care market – success starts with market access.In this Podcast episode Dr. Stefan Walzer confronts the Swiss expert Michael Zuercher with his perspective on Market Access to Switzerland. Furthermore they are discussing the right commercial planning in the context of a successful market access submission in Switzerland. Even though the Swiss market is low in volumes due to a limited number of patients in comparison to other European countries, it is a very attractive market with unique entrance options such as “early paid access”! Take the chance to stay connected and subscribe with your favorite podcasting platform.For more information about MArS Market A...2021-12-0132 minMAP - Market Access PodcastProf. Peter Zweifel & Door Vonk - Digital innovation - from theory into practice!In this Podcast episode, Dr. Stefan Walzer is discussing innovation theory from an economics perspective together with Prof. Peter Zweifel from the University of Zürich. Afterwards theory will be confronted with real life! Door Vonk talsk about founding the company „Tired of Cancer“ in the context of innovation theory.Take the chance to stay connected and subscribe with your favorite podcasting platform.For more information about MArS Market Access and Pricing Strategy visit: marketaccess-pricingstrategy.de2021-11-151h 01MAP - Market Access PodcastBibiane Schulte-Bosse - How to fight well in AMNOG negotiations.In this Podcast episode, Dr. Stefan Walzer is explaining the details of the price negotiations within the AMNOG process together with negotiating expert and lawyer Bibiane Schulte-Bosse. Get into the hot areas of AMNOG – the negotiations and let us know in case you might have any questions.Take the chance to stay connected and subscribe with your favorite podcasting platform.For more information about MArS Market Access and Pricing Strategy visit: marketaccess-pricingstrategy.de2021-11-0134 minMAP - Market Access PodcastProf. Dr. David Matusiewicz & Dr. Anne Sophie Geier - 1 year DIGAs. Is the "fast track process" for digital health applications successful?In this Podcast episode, Dr. Stefan Walzer is reflecting on 1 year DIGAswith the leading question whether the "fast track process" for digital health applications is successful?Additionally, the two digital health experts, Prof. Dr. David Matusiewicz from the FOM Universtity and Dr. Anne Sophie Geier from the head association of digital healthcare SVDGV, will also discuss the status of digitalization in the German health care system.Get into the latest digital health care discussions and let us know in case you might have any questions.Take the chance to stay c...2021-10-1528 minMAP - Market Access PodcastRemo Christen – Early paid access in Switzerland – Switzerland, wonderland??In this Podcast episode, Dr. Stefan Walzer is discussing the specifics of the Swiss market access & reimbursement specifics including the famous article 71, which allows an early paid access. Who else could better speak about the Swiss system with him than Remo Christen? Remo is working since > 20 years in the Swiss market access environment in a leading role at Roche’s Swiss affiliate. In this episode, listeners will learn the specifics of the Swiss culture, the reimbursement process also in comparison to the German AMNOG and why Switzerland is attractive for drug launches.Subscribe wi...2021-10-0134 minMAP - Market Access PodcastProf. Dr. Wagschal - What can we expect from the upcoming elections in Germany?In this Podcast episode, Dr. Stefan Walzer is speaking to Prof. Dr. Wagschal from the University of Freiburg about the upcoming elections in Germany.They are discussing latest forecasts and potential policy implications. Prof. Wagschal also explains limitations of forecasts and dynamics of recent elections.Another important part is in the potential (new) coalitions and their likely impact on the health care market.Subscribe at your favourite podcasting platform and for more information about MArS Market Access and Pricing Strategy visit:marketaccess-pricingstrategy.de2021-09-1535 minMAP - Market Access PodcastDr. Mathias Flume - AMNOG will change in 2022, but how?In this Podcast episode, Dr. Stefan Walzer is talking with Dr. Mathias Flume about the AMNOG process as well as interesting details about the market access process in Germany.Mathias is a core stakeholder within the regional payer system in Germany at one of the most innovative Statutory Health Insurance Physician Associations (KV Westphalia-Lippe). Mathias brings the payer view into the discussion of 10 years AMNOG. Success or failure?2021-09-0234 min